

# Peter Bader

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9361733/publications.pdf>

Version: 2024-02-01

301  
papers

14,495  
citations

28274

55  
h-index

24258

110  
g-index

310  
all docs

310  
docs citations

310  
times ranked

14345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	27.0	3,680
2	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4381-4389.	1.6	478
3	Determinants of Antileukemia Effects of Allogeneic NK Cells. <i>Journal of Immunology</i> , 2004, 172, 644-650.	0.8	397
4	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	1.4	340
5	Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 377-384.	1.6	337
6	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 1301-1309.	13.7	324
7	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. <i>Blood</i> , 2005, 105, 410-419.	1.4	291
8	Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1696-1705.	1.6	231
9	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	3.5	230
10	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
11	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
12	Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donorsâ€”The ALL-SCT-BFM-2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1265-1274.	1.6	186
13	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 295-307.	1.6	163
14	CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. <i>Haematologica</i> , 2010, 95, 651-659.	3.5	151
15	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	5.2	151
16	Similar outcome of upfrontâ€”unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <sc>UK</sc> Paediatric <sc>BMT</sc> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <sc>EBMT</sc>. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	2.5	146
17	Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. <i>Cytotherapy</i> , 2017, 19, 235-249.	0.7	142
18	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , the, 2019, 6, e573-e584.	4.6	140

#	ARTICLE	IF	CITATIONS
19	Selection and expansion of natural killer cells for NK cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 477-484.	4.2	137
20	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	1.4	127
21	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117
22	Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. <i>British Journal of Haematology</i> , 2005, 128, 774-782.	2.5	116
23	Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1275-1284.	1.6	110
24	Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. <i>British Journal of Haematology</i> , 2000, 111, 635-640.	2.5	107
25	Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol. <i>Frontiers in Oncology</i> , 2013, 3, 118.	2.8	103
26	Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. <i>British Journal of Haematology</i> , 2003, 121, 411-418.	2.5	100
27	Identification of a novel class of human adherent CD34 <sup>+</sup> stem cells that give rise to SCID-repopulating cells. <i>Blood</i> , 2003, 101, 869-876.	1.4	100
28	Long-term outcome after haploidentical stem cell transplantation in children. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 281-287.	1.4	99
29	Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. <i>Blood</i> , 2011, 118, 5681-5688.	1.4	92
30	Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 121, 886-891.	2.5	89
31	Transplantation of highly purified CD34 <sup>+</sup> progenitor cells from unrelated donors in pediatric leukemia. <i>Blood</i> , 2003, 101, 1630-1636.	1.4	89
32	Transplantation of a combination of CD133 <sup>+</sup> and CD34 <sup>+</sup> selected progenitor cells from alternative donors. <i>British Journal of Haematology</i> , 2004, 124, 72-79.	2.5	86
33	A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. <i>British Journal of Haematology</i> , 2001, 114, 422-432.	2.5	85
34	The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. <i>Cytotherapy</i> , 2012, 14, 91-103.	0.7	84
35	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2016, 127, 3281-3290.	1.4	83
36	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81

#	ARTICLE	IF	CITATIONS
37	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	30.7	79
38	Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. <i>Haematologica</i> , 2016, 101, 985-994.	3.5	78
39	IL-2-activated haploidentical NK cells restore NKG2D-mediated NK cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. <i>European Journal of Immunology</i> , 2010, 40, 3255-3267.	2.9	77
40	Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). <i>Bone Marrow Transplantation</i> , 2018, 53, 852-862.	2.4	77
41	Haploidentical transplantation for acute lymphoblastic leukemia in childhood. <i>Blood Reviews</i> , 2004, 18, 181-192.	5.7	76
42	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1187-1211.	2.0	76
43	IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study. <i>PLoS ONE</i> , 2011, 6, e27351.	2.5	76
44	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	4.8	71
45	A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2017, 8, 676.	4.8	70
46	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 895-895.	1.4	70
47	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	5.0	70
48	Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 80.	6.2	68
49	Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 27-34.	1.6	67
50	Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 24-29.	2.5	66
51	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1710-1718.	10.7	65
52	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	6.2	65
53	Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. <i>Haematologica</i> , 2010, 95, 1579-1586.	3.5	63
54	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 221-221.	1.4	62

#	ARTICLE	IF	CITATIONS
55	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	2.4	61
56	Genetically engineered CAR NK cells display selective cytotoxicity against FLT3 <sup>+</sup> ALL and inhibit <i>in vivo</i> leukemia growth. <i>International Journal of Cancer</i> , 2019, 145, 1935-1945.	5.1	60
57	Graft-Versus-Ewing Sarcoma Effect and Long-Term Remission Induced by Haploidentical Stem-Cell Transplantation in a Patient With Relapse of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2005, 23, 242-244.	1.6	51
58	Chimeric antigen receptor <sup>+</sup> engineered cytokine <sup>+</sup> induced killer cells overcome treatment resistance of pre-B <sup>+</sup> cell acute lymphoblastic leukemia and enhance survival. <i>International Journal of Cancer</i> , 2016, 139, 1799-1809.	5.1	51
59	Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. <i>Investigational New Drugs</i> , 2005, 23, 99-109.	2.6	50
60	Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. <i>British Journal of Haematology</i> , 2018, 180, 82-89.	2.5	50
61	Adult Stem Cells as an Alternative Source of Multipotential (Pluripotential) Cells in Regenerative Medicine. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 107-117.	1.3	48
62	Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1353-1359.	7.0	48
63	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	4.8	48
64	Severe Bullous Pemphigoid in an Infant: Successful Treatment with Rituximab. <i>Pediatric Dermatology</i> , 2008, 25, 462-465.	0.9	47
65	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. <i>Haematologica</i> , 2019, 104, e543-e546.	3.5	47
66	Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 331-337.	1.7	46
67	$\beta$ -D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2605-2610.	3.9	46
68	Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2005, 129, 542-549.	2.5	45
69	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1629-1642.	2.0	44
70	Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 194-205.	2.0	42
71	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42
72	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1540-1551.	2.4	42

#	ARTICLE	IF	CITATIONS
73	Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. <i>Haematologica</i> , 2013, 98, 1609-1616.	3.5	41
74	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 467-474.	2.0	41
75	Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S263-S264.	0.4	41
76	Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia. <i>Frontiers in Immunology</i> , 2018, 9, 2495.	4.8	41
77	Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. <i>British Journal of Haematology</i> , 2005, 128, 649-658.	2.5	40
78	Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 33-39.	1.4	40
79	CD34 <sup>+</sup> selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 90-99.	2.5	39
80	Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM" Outcome Report of 92 Patients. <i>Cells</i> , 2019, 8, 1577.	4.1	38
81	Down-regulation of protein kinase C $\delta$ by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. <i>Cancer Letters</i> , 2004, 209, 177-185.	7.2	37
82	The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2816.	4.8	37
83	Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. <i>Frontiers in Oncology</i> , 2012, 2, 32.	2.8	36
84	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 595.	4.8	36
85	Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. <i>Haematologica</i> , 2016, 101, e153-e156.	3.5	36
86	Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system. <i>Journal of Immunological Methods</i> , 2002, 271, 167-175.	1.4	34
87	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	3.5	34
88	Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. <i>Oncotarget</i> , 2017, 8, 66137-66153.	1.8	34
89	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. <i>Blood</i> , 2008, 111, 1124-1127.	1.4	33
90	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	7.1	33

#	ARTICLE	IF	CITATIONS
91	Distinct contributions of CD4+ and CD8+naive and memory T-cell subsets to overall T-cell receptor repertoire complexity following transplantation of T-cell-depleted CD34-selected hematopoietic progenitor cells from unrelated donors. <i>Blood</i> , 2002, 100, 1915-1918.	1.4	31
92	Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections. <i>Frontiers in Immunology</i> , 2017, 8, 109.	4.8	30
93	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30
94	Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. <i>Journal of Immunological Methods</i> , 2008, 335, 41-45.	1.4	29
95	Mesenchymal stromal cells derived from CD271+ bone marrow mononuclear cells exert potent allosuppressive properties. <i>Cytotherapy</i> , 2011, 13, 1193-1204.	0.7	29
96	Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2012, 7, e50248.	2.5	29
97	Monitoring of Hematopoietic Chimerism after Transplantation for Pediatric Myelodysplastic Syndrome: Real-Time or Conventional Short Tandem Repeat PCR in Peripheral Blood or Bone Marrow?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1918-1925.	2.0	29
98	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	7.0	28
99	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1281-1292.	2.0	28
100	Evaluation of Murex CMV DNA Hybrid Capture Assay for Detection and Quantitation of Cytomegalovirus Infection in Patients following Allogeneic Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1333-1337.	3.9	28
101	Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 87-95.	2.0	27
102	Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1848-1855.	2.0	27
103	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. <i>Blood Advances</i> , 2020, 4, 1760-1769.	5.2	27
104	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	7.2	27
105	Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 821-833.	4.2	26
106	Impact of the initial fitness level on the effects of a structured exercise therapy during pediatric stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26851.	1.5	26
107	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1350-1358.	2.0	25
108	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25

#	ARTICLE	IF	CITATIONS
109	Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2743.	4.8	25
110	Anticancer Drug-mediated Induction of Multidrug Resistance-associated Genes and Protein Kinase C Isozymes in the T-Lymphoblastoid Cell Line CCRF-CEM and in Blasts from Patients with Acute Lymphoblastic Leukemias. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 896-903.	1.7	24
111	WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?. <i>European Journal of Haematology</i> , 2004, 73, 25-28.	2.2	24
112	Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 741-746.	3.5	24
113	Treatment of Infantile Inflammatory Bowel Disease and Autoimmunity by Allogeneic Stem Cell Transplantation in LPS-Responsive Beige-Like Anchor Deficiency. <i>Frontiers in Immunology</i> , 2017, 8, 52.	4.8	24
114	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. <i>Leukemia</i> , 2020, 34, 1694-1700.	7.2	24
115	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	2.4	24
116	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1126-1136.	2.4	23
117	Sequence Polymorphism Systems for Quantitative Real-Time Polymerase Chain Reaction to Characterize Hematopoietic Chimerism—High Informativity and Sensitivity As Well As Excellent Reproducibility and Precision of Measurement. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 73-84.	1.2	23
118	Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. <i>Haematologica</i> , 2006, 91, 788-94.	3.5	23
119	Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 403-411.	1.7	22
120	Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3+CD4+ ratio in severe GvHD or relapse. <i>Journal of Immunological Methods</i> , 2011, 373, 36-44.	1.4	22
121	Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. <i>Pediatric Transplantation</i> , 2016, 20, 1132-1136.	1.0	22
122	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 799-805.	2.0	22
123	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 441-451.	2.4	22
124	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020, 11, 581468.	4.8	22
125	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Pediatrics</i> , 2021, 9, 705179.	1.9	22
126	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	5.2	22



#	ARTICLE	IF	CITATIONS
127	Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. <i>Cytotherapy</i> , 2014, 16, 835-844.	0.7	21
128	Psychophysical effects of an exercise therapy during pediatric stem cell transplantation: a randomized controlled trial. <i>Bone Marrow Transplantation</i> , 2019, 54, 1827-1835.	2.4	21
129	Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study. <i>Frontiers in Immunology</i> , 2018, 9, 1841.	4.8	20
130	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 70-70.	1.4	20
131	Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. <i>Anticancer Research</i> , 2002, 22, 4229-32.	1.1	20
132	NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2015, 6, 583.	4.8	19
133	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	7.2	19
134	Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations. <i>Transplant International</i> , 2020, 33, 762-772.	1.6	19
135	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3703-3703.	1.4	19
136	Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. <i>Oncotarget</i> , 2016, 7, 70959-70968.	1.8	19
137	Atypical Manifestation of LPS-Responsive Beige-Like Anchor Deficiency Syndrome as an Autoimmune Endocrine Disorder without Enteropathy and Immunodeficiency. <i>Frontiers in Pediatrics</i> , 2016, 4, 98.	1.9	18
138	The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells. <i>Frontiers in Immunology</i> , 2017, 8, 202.	4.8	18
139	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. <i>Journal of Clinical Oncology</i> , 2019, 37, 3493-3506.	1.6	18
140	Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1218.	4.8	18
141	Treosulfan—fludarabine—thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1996-2007.	2.4	18
142	Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 443-452.	1.7	17
143	Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 825-836.	1.8	17
144	Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <i>Pediatric Pulmonology</i> , 2020, 55, 1725-1735.	2.0	17

#	ARTICLE	IF	CITATIONS
145	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. <i>Blood</i> , 2014, 124, 2292-2292.	1.4	17
146	PRIMARY INTESTINAL ASPERGILLOSIS AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 465-466.	2.0	16
147	Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus. <i>Cytotherapy</i> , 2015, 17, 1139-1151.	0.7	16
148	Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2230-2239.	1.5	16
149	Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 1847-1858.	2.4	16
150	Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S126-S127.	2.0	16
151	Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial. <i>Blood</i> , 2015, 126, 4344-4344.	1.4	16
152	Outcome of Relapse After Allogeneic Transplantation for Childhood Acute Lymphoblastic Leukemia In Complete Remission. A Study of the Pediatric Diseases and Acute Leukemia Working Parties of the EBMT Group. <i>Blood</i> , 2010, 116, 1291-1291.	1.4	16
153	Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. <i>Pathologie Et Biologie</i> , 2005, 53, 159-161.	2.2	15
154	Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation. <i>European Journal of Pediatrics</i> , 2014, 173, 1399-1403.	2.7	15
155	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. <i>Cytotherapy</i> , 2015, 17, 1667-1674.	0.7	15
156	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 110-116.	2.4	15
157	Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients. <i>Journal of Clinical Apheresis</i> , 2020, 35, 398-405.	1.3	15
158	Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. <i>Journal of Translational Medicine</i> , 2021, 19, 145.	4.4	15
159	Autologous Transplantation with Peripheral Blood Stem Cells in Children and Young Adults After Myeloablative Treatment: Nonrandomized Comparison Between GM-CSF and G-CSF for Mobilization. <i>Stem Cells and Development</i> , 1995, 4, 307-314.	1.0	14
160	SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy. <i>Frontiers in Pediatrics</i> , 2014, 2, 75.	1.9	14
161	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. <i>European Journal of Cancer</i> , 2019, 122, 61-71.	2.8	14
162	Stem Cell Transplantation for Diamond-Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). <i>Transplantation and Cellular Therapy</i> , 2021, 27, 274.e1-274.e5.	1.2	14

#	ARTICLE	IF	CITATIONS
163	Myeloablative Chemo-Conditioning for First Hematopoietic STEM CELL Transplantation in Children with ACUTE Lymphoblastic Leukemia in First or Second Remission. <i>Blood</i> , 2014, 124, 546-546.	1.4	14
164	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 784024.	1.9	13
165	Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. <i>Transfusion</i> , 2016, 56, 2336-2345.	1.6	12
166	Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL – results of the ALL-SCT 2003 trial. <i>British Journal of Haematology</i> , 2018, 183, 104-109.	2.5	12
167	Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia. <i>Frontiers in Immunology</i> , 2019, 10, 2785.	4.8	12
168	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). <i>Bone Marrow Transplantation</i> , 2020, 55, 1744-1753.	2.4	12
169	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1551-1551.	1.4	12
170	Generation and flow cytometric quality control of clinical-scale TCR $\alpha$ /CD19-depleted grafts. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 126-135.	1.5	11
171	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. <i>Bone Marrow Transplantation</i> , 2021, 56, 257-266.	2.4	11
172	TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 389-389.	1.4	11
173	CD3/CD19 Depleted Grafts for Haploidentical Stem Cell Transplantation in Children: Results of a Pilot Study.. <i>Blood</i> , 2006, 108, 3121-3121.	1.4	11
174	Hematopoietic Stem Cell Transplantation (HSCT) after a Myeloablative Conditioning Regimen in Children with Refractory Cytopenia (RC): Results of a Retrospective Analysis from the EWOG-MDS Group.. <i>Blood</i> , 2007, 110, 251-251.	1.4	11
175	Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial. <i>Bone Marrow Transplantation</i> , 2018, 53, 891-894.	2.4	10
176	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	2.4	10
177	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	1.2	10
178	Human leukocyte antigen DR surface expression on CD14+ monocytes during adverse events after hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 265-273.	1.8	9
179	Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 101, 791-797.	2.2	9
180	Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia – A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP. <i>American Journal of Hematology</i> , 2019, 94, 880-890.	4.1	9

#	ARTICLE	IF	CITATIONS
181	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. <i>American Journal of Transplantation</i> , 2019, 19, 1798-1805.	4.7	9
182	The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children. <i>Journal of Clinical Medicine</i> , 2021, 10, 3506.	2.4	9
183	Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia. <i>Journal of Clinical Immunology</i> , 2021, 41, 1878-1892.	3.8	9
184	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. <i>Blood</i> , 2018, 132, 168-168.	1.4	9
185	A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 69-78.	5.9	9
186	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. <i>Blood Advances</i> , 2021, 5, 262-273.	5.2	9
187	SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1194-1197.	2.9	9
188	Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization. <i>BMC Hematology</i> , 2005, 5, 1.	2.6	8
189	Stem cell transplantation for polycythemia vera. <i>Pediatric Blood and Cancer</i> , 2008, 50, 124-126.	1.5	8
190	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
191	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Pharmacology</i> , 2017, 8, 451.	3.5	8
192	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	2.4	8
193	Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28523.	1.5	8
194	The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study. <i>British Journal of Haematology</i> , 2021, 194, 879-887.	2.5	8
195	Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 777108.	1.9	8
196	In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy. <i>Journal of Translational Medicine</i> , 2016, 14, 264.	4.4	7
197	Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. <i>Cytotherapy</i> , 2018, 20, 839-850.	0.7	7
198	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2438-2446.	2.0	7

#	ARTICLE	IF	CITATIONS
199	Tracking of Infused Mesenchymal Stem Cells in Injured Pulmonary Tissue in Atm-Deficient Mice. <i>Cells</i> , 2020, 9, 1444.	4.1	7
200	Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. <i>Cancers</i> , 2021, 13, 1443.	3.7	7
201	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	1.4	7
202	Understanding the Role of LFA-1 in Leukocyte Adhesion Deficiency Type I (LAD I): Moving towards Inflammation?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3578.	4.1	7
203	Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. <i>British Journal of Haematology</i> , 2000, 111, 635-640.	2.5	6
204	Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge. <i>Expert Review of Hematology</i> , 2014, 7, 291-300.	2.2	6
205	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
206	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2019, 54, 2060-2071.	2.4	6
207	Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e27-e37.	2.0	6
208	Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial. <i>Blood</i> , 2013, 122, 3315-3315.	1.4	6
209	Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. <i>Clinical Drug Investigation</i> , 2021, 41, 929-939.	2.2	6
210	Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 96-102.	2.0	5
211	Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant Centers. <i>Children</i> , 2021, 8, 615.	1.5	5
212	Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). <i>Blood</i> , 2011, 118, 247-247.	1.4	5
213	Analysis of Chimerism After Stem Cell Transplantation. , 2004, 91, 247-264.		4
214	Simultaneous Control of Third-Degree Graft-Versus-Host Disease and Prevention of Recurrence of Juvenile Myelomonocytic Leukemia (JMML) With 6-Mercaptopurine Following Fulminant JMML Relapse Early After KIR Mismatched Bone Marrow Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 672-674.	0.6	4
215	Haploidentical Stem Cell Transplantation in Childhood. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 37-44.	0.3	4
216	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. <i>Blood Advances</i> , 2019, 3, 3143-3156.	5.2	4

#	ARTICLE	IF	CITATIONS
217	AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?. Bone Marrow Transplantation, 2019, 54, 737-745.	2.4	4
218	Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. Pediatric Hematology and Oncology, 2013, 30, 349-366.	0.8	3
219	Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus. Journal of Leukocyte Biology, 2016, 100, 1297-1310.	3.3	3
220	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. Bone Marrow Transplantation, 2019, 54, 53-62.	2.4	3
221	The Phenotype and Functional Activity of Mesenchymal Stromal Cells in Pediatric Patients with Non-Malignant Hematological Diseases. Cells, 2020, 9, 431.	4.1	3
222	Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children. Wiener Klinische Wochenschrift, 2021, 133, 41-51.	1.9	3
223	ABO incompatible graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	2.4	3
224	How can fertility counseling be implemented for every newly diagnosed pediatric patient facing gonadotoxic treatment?-A single-center experience. Annals of Hematology, 2021, 100, 2831-2841.	1.8	3
225	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. Blood, 2018, 132, 1375-1375.	1.4	3
226	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. Blood, 2018, 132, 604-604.	1.4	3
227	Alternative Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe. Blood, 2018, 132, 4645-4645.	1.4	3
228	Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 2139-2139.	1.4	3
229	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. Blood, 2006, 108, 2681-2681.	1.4	3
230	Clinical Impact Of Post-Transplant Chimerism Monitoring In CD33/34 Bone Marrow Subpopulations and Whole Blood In Pediatric AML: Prospective Comparison Of Highly Sensitive Real Time Sequence Polymorphism PCR Versus Gold-Standard Conventional STR-PCR. Blood, 2013, 122, 411-411.	1.4	3
231	Defibrotide for Prophylaxis of Hepatic Venooclusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. Blood, 2015, 126, 4310-4310.	1.4	3
232	Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience. Oncotarget, 2019, 10, 6138-6151.	1.8	3
233	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. Blood, 2013, 122, 4591-4591.	1.4	3
234	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3211-3211.	1.4	3

#	ARTICLE	IF	CITATIONS
235	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3824-3824.	1.4	3
236	Ex Vivo Expansion of Normal Progenitor Cells from Acute Myeloid Leukemia Cell-Contaminated CD34+Peripheral Blood Progenitor Cells after Mafosfamide Purging. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 777-785.	1.8	2
237	Defibrotide for Prophylaxis of Hepatic Venno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S25-S26.	2.0	2
238	Preemptive Treatment of Minimal Residual Disease (MRD) with IL-15-Activated Cytokine-Induced Killer Cells for the Prevention of Relapse in Leukemia Patients after Allogeneic Stem Cell Transplantation – Results of a Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S43.	2.0	2
239	Pregnancy Rates and Pregnancy Outcomes after Hematopoietic Stem Cell Transplantation in Childhood: a Cross-Sectional Survey of the EBMT Pediatric WP. <i>Blood</i> , 2018, 132, 3418-3418.	1.4	2
240	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. <i>Blood</i> , 2014, 124, 1215-1215.	1.4	2
241	Fetomaternal Microchimerism Is Associated with Better Outcome in Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1242-1242.	1.4	2
242	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTc, the I-BFM and the Westhafen-Intercontinental-Group. <i>Blood</i> , 2016, 128, 985-985.	1.4	2
243	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	1.4	2
244	A New Perspective for Bone Tissue Engineering: Human Mesenchymal Stromal Cells Well-Survive Cryopreservation on Î <sup>2</sup> -TCP Scaffold and Show Increased Ability for Osteogenic Differentiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1425.	4.1	2
245	Fatal immune-mediated pancytopenia and a TRALI-like syndrome associated with high titers of recipient-type antibodies against donor-derived peripheral blood cells after allogeneic bone marrow transplantation following dose reduced conditioning. <i>Haematologica</i> , 2004, 89, ECR12.	3.5	2
246	Single Center Real Life Experiences in the Treatment of Pediatric, Adolescent and Young Adult ALL Patients Using Commercially Available CAR-T-Cells in Germany – Susceptibility to Bridging Chemotherapy Predicts Response.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S262.	2.0	1
247	Depletion of CD45RA+ T cells: Advantages and disadvantages of different purification methods. <i>Journal of Immunological Methods</i> , 2021, 492, 112960.	1.4	1
248	Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients. <i>Blood</i> , 2018, 132, 603-603.	1.4	1
249	Pediatric Fanconi Anemia With Secondary AML: A Retrospective Outcome Report From The German AML-BFM Group. <i>Blood</i> , 2013, 122, 1414-1414.	1.4	1
250	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	1.4	1
251	Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 796-796.	1.4	1
252	Safety and Tolerability of Donor Type Red Blood Cell Transfusion before Allogeneic Stem Cell Transplantation in Children with Major ABO Mismatch. <i>Blood</i> , 2016, 128, 3415-3415.	1.4	1

#	ARTICLE	IF	CITATIONS
253	Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study. <i>Blood</i> , 2017, 130, 911-911.	1.4	1
254	Allogeneic HSCT from Unrelated and Sibling Donors are Equal for Children with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S228-S229.	2.0	0
255	Incidence and Mortality of Adenovirus Infection After Pediatric Allogeneic SCT – A Comparison Between Bone Marrow and CD3/19 Depleted PBSC. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S242.	2.0	0
256	HLA Identical Siblings Are the Best Donors for Children with ALL. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S179-S180.	2.0	0
257	Quantitative Monitoring of Minimal Residual Disease after Allogeneic Stem Cell Transplantation in Relapsed Childhood ALL Allows the Identification of Impending Relapse – Results of the ALL BFM SCT 2003 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S85-S86.	2.0	0
258	Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring Is an Effective Strategy to Prevent Relapse after Allogeneic Stem Cell Transplantation in Children with ALL: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S209.	2.0	0
259	Cotransplantation of preactivated mesenchymal stromal cells with hematopoietic stem cells improves T-cell regeneration. <i>Cytotherapy</i> , 2015, 17, S8.	0.7	0
260	Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdwp of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S22-S23.	2.0	0
261	An Exponential Regression Model Reveals the Continuous Development of B Cell Subpopulations Used as Reference Values in Children. <i>Frontiers in Pediatrics</i> , 2018, 6, 121.	1.9	0
262	Serving his patients with passion and dedication – Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer. <i>Bone Marrow Transplantation</i> , 2020, 55, 1209-1210.	2.4	0
263	Control of Fulminant Juvenile Myelomonocytic Leukemia (JMML) Relapse and Gut GvHD III <sup>o</sup> with Purinethol Early after Unrelated Donor BMT.. <i>Blood</i> , 2004, 104, 5089-5089.	1.4	0
264	Improved Immune Reconstitution with Low Incidence of Severe Graft-Versus-Host Disease after Transplantation of CD34+ or CD133+ Enriched Stem Cells with Add-Back of Ten Million T-Cells Per Kg.. <i>Blood</i> , 2004, 104, 1239-1239.	1.4	0
265	Pediatric Patients Transplanted with Positive Selected Stem Cells from Alternative Donors Have a Low Incidence of CMV Dnaemia.. <i>Blood</i> , 2004, 104, 5192-5192.	1.4	0
266	GvHD and Engraftment after Haploidentical Stem Cell Transplantation. A Comparison of 3 Immunomagnetic Selection Procedures.. <i>Blood</i> , 2004, 104, 5019-5019.	1.4	0
267	Haploidentical Stem Cell Transplantation in Children: A Comparison between Positive Selection of Stem Cells and Depletion of T- and B-Cells.. <i>Blood</i> , 2005, 106, 1420-1420.	1.4	0
268	Boosts with Highly Purified Stem Cells Can Improve Hematopoietic Regeneration after Allogeneic Transplantation from Alternative Donors.. <i>Blood</i> , 2005, 106, 2917-2917.	1.4	0
269	Transplantation of Positive Selected Peripheral Stem Cells with Add-Back of T Cells from Unrelated Donors in Children: Favourable Survival and Low Incidence of GvHD.. <i>Blood</i> , 2006, 108, 2900-2900.	1.4	0
270	The EuroChimerism Concept for a Standardized Approach to Chimerism Analysis Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 621-621.	1.4	0



#	ARTICLE	IF	CITATIONS
271	Preemptive Immunotherapy with Highly Purified CD56+/CD3 <sup>+</sup> Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers.. Blood, 2006, 108, 411-411.	1.4	0
272	Retransplantation with Stem Cells from Mismatched Related Donors after Graft Rejection in Pediatric Patients.. Blood, 2006, 108, 2955-2955.	1.4	0
273	Phenotypic and Functional Characterization of Mesenchymal Stromal Cells Derived from CD271 <sup>+</sup> Bone Marrow Mononuclear Cells and Mesenchymal Stromal Cells Derived through Plastic Adherence.. Blood, 2007, 110, 1921-1921.	1.4	0
274	Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007. Blood, 2008, 112, 567-567.	1.4	0
275	Long Term Survival and Relapse Rate After Transplantation of Highly T and B Cell Depleted Stem Cells From Alternative Donors in Pediatric Patients with Acute Lymphatic Leukemia.. Blood, 2009, 114, 4333-4333.	1.4	0
276	Allogeneic Hematopoietic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003. Blood, 2010, 116, 530-530.	1.4	0
277	Successful Haploidentical Stemcell Transplantation In a Patient with Fanconi Anemia and AML.. Blood, 2010, 116, 4586-4586.	1.4	0
278	WT1 Expression at the Diagnosis of Childhood AML Has No Prognostic Value but Corresponds with the Biological Characteristics of Leukemic Cells - Results From European Multicenter Study.. Blood, 2010, 116, 1684-1684.	1.4	0
279	Monitoring of Minimal Residual Disease After Allogeneic Stem Cell Transplantation In Relapsed Childhood ALL Allows The Identification Of Impending Relapse - Results Of The ALL BFM SCT 2003 Trial. Blood, 2013, 122, 1995-1995.	1.4	0
280	Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT. Blood, 2014, 124, 256-256.	1.4	0
281	CMV-Specific Cytokine-Induced Killer Cells Comprise Concomitant Cytotoxicity Against Leukemia and Cytomegalovirus. Blood, 2014, 124, 5814-5814.	1.4	0
282	Repetitive Infusions of Cytokine-Induced Killer (CIK) Cells for Treatment of Impending Relapse in High-Risk Leukemia Patients after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 2438-2438.	1.4	0
283	Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Single Center Experience. Blood, 2014, 124, 3953-3953.	1.4	0
284	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. Blood, 2014, 124, 2570-2570.	1.4	0
285	An Accelerated CD8 <sup>+</sup> , but Not CD4 <sup>+</sup> , T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. Blood, 2015, 126, 1929-1929.	1.4	0
286	Treatment of Iron Overload in Transfusion-Dependent Anemias Post Hematopoietic Stem Cell Transplantation: When to Start? When to Stop?. Blood, 2015, 126, 3369-3369.	1.4	0
287	Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission. Blood, 2015, 126, 4384-4384.	1.4	0
288	Fertility Preservation in Pediatric and Adolescent Patients Undergoing HSCT: a Cross-Sectional Survey of the EBMT Pediatric WP. Blood, 2016, 128, 4611-4611.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases. <i>Blood</i> , 2016, 128, 3398-3398.	1.4	0
290	Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 2172-2172.	1.4	0
291	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 601-601.	1.4	0
292	Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Report on Behalf of the EBMT Paediatric Diseases Working Party. <i>Blood</i> , 2017, 130, 76-76.	1.4	0
293	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	1.4	0
294	Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT. <i>Blood</i> , 2018, 132, 1307-1307.	1.4	0
295	Stem Cell Transplantation for Pediatric Patients with Non-Anaplastic Peripheral T-Cell Lymphoma on Behalf of the EBMT-Pediatric Diseases Working Party. <i>Blood</i> , 2018, 132, 5787-5787.	1.4	0
296	Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT. <i>Blood</i> , 2018, 132, 3369-3369.	1.4	0
297	The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT. <i>Blood</i> , 2018, 132, 3462-3462.	1.4	0
298	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. <i>Blood</i> , 2018, 132, 3354-3354.	1.4	0
299	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with GATA2-Related Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 2033-2033.	1.4	0
300	Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study. <i>Blood</i> , 2021, 138, 2862-2862.	1.4	0
301	Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0